SERA:NASDAQ, Sera Prognostics, Inc.
SERA stock overview
Sera Prognostics, Inc. (SERA:NASDAQ) closed at $2.03 on October 23, 2026,
down 0.49% on the day.
The stock trades 48.6% below its 52-week high of $3.95
and 30.1% above its 52-week low of $1.56.
Over the past year, it lost 44.4%.
Sera Prognostics, Inc. is part of the Health Care sector.
Key figures
- Price
- $2.03
- Day change
- -0.49%
- Volume
- 25,072
- Average volume
- 24,146
- Market cap
- 80M+
- 52-week range
- $1.56 – $3.95
- 50-day average
- $2.05
- 200-day average
- $2.18
Price action over the past year
In 252 trading sessions since October 23, 2025, SERA closed higher on 114 days (45%).
Its best day was November 12, 2025 (+15.99%) and its worst was November 6, 2025 (-12.62%).
The stock moved 10% or more in a single session 11 times.
It opened at least 5% above the previous day's high 1 time.
Recent signals
SERA news
-
Oct 21, 2026:
SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF THIRD QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON NOVEMBER 4, 2026
-
Aug 25, 2026:
1 in 10 U.S. Babies Are Born Too Early. A Leading OB-GYN Says Most Mothers Can Learn Their Risk by Week 21, and Do Something About It.
-
Aug 19, 2026:
Sera (SERA) Q2 2026 Earnings Call Transcript
-
Aug 19, 2026:
SERA PROGNOSTICS APPOINTS SCOTT GLEASON CHIEF FINANCIAL OFFICER
-
Aug 13, 2026:
Sera Prognostics, Inc. Q2 2026 Earnings Call Summary
-
Aug 13, 2026:
Sera Prognostics Inc (SERA) (Q2 2026) Earnings Call Highlights: Payer Momentum Builds with ...
-
Aug 13, 2026:
Sera Prognostics Q2 Earnings Call Highlights
-
Aug 12, 2026:
Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Misses Revenue Estimates
About Sera Prognostics, Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, and other pregnancy complications.
Similar stocks
Find more stocks like SERA with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.